RT Book, Section
A1 Henderson, Cory
A1 Rosica, Dillenia
A1 Dorbala, Sharmila
A2 Heller, Gary V.
A2 Hendel, Robert C.
SR Print(0)
ID 1190157719
T1 Imaging Cardiac Amyloidosis
T2 Nuclear Cardiology: Practical Applications, 4e
YR 2022
FD 2022
PB McGraw Hill LLC
PP New York, NY
SN 9781264257201
LK accesscardiology.mhmedical.com/content.aspx?aid=1190157719
RD 2024/04/19
AB KEY  POINTSCardiac  transthyretin  (ATTR)  amyloidosis  is  increasingly  recognized  as  a  common  underlying  cause  of  heart  failure  with  preserved  ejection  fraction  in  the  elderly.Echocardiography  is  often  the  first  test  that  raises  the  suspicion  of  amyloidosis;  but  echocardiographic  features  cannot  definitively  distinguish  amyloidosis  from  nonamyloid  hypertrophic  heart  disease  or  light  chain  (AL)  from  ATTR  cardiac  amyloidosis.Cardiac  magnetic  resonance  imaging  with  tissue  characterization  using  gadolinium  can  distinguish  amyloidosis  from  nonamyloid  hypertrophic  heart  disease  but  cannot  distinguish  AL  from  ATTR  cardiac  amyloidosis.Cardiac  scintigraphy  with  bone  avid  radiotracers  can  definitively  identify  ATTR  cardiac  amyloidosis  noninvasively,  in  select  patients,  avoiding  the  need  for  endomyocardial  biopsy.Targeted  amyloid-binding  positron  emission  tomography  tracers  are  emerging  as  quantitative  tools  to  image  AL  and  ATTR  cardiac  amyloidosis.Tafamidis  is  a  therapy  that  stabilizes  transthyretin  protein  and  has  been  FDA  approved  for  the  treatment  of  ATTR  cardiac  amyloidosis,  and  additional  agents  for  treatment  are  undergoing  clinical  trials.